Abstract

Species of Myrcia are used by indigenous people and in traditional communities in Brazil for the treatment of Diabetes mellitus. We investigated the hypoglycemic effect of the extract of leaves of Myrcia bella in diabetic mice. The chemical fingerprinting of the 70% EtOH extract characterized as main constituents flavonoid aglycones, flavonoid-O-glycosides, and acylated flavonoid-O-glycosides derivatives of quercetin and myricetin. Mice were treated with saline or extract of M. bella (300 or 600 mg/Kg b.w.) for 14 days. Body weight and water and food intake were measured every day. Fasting blood glucose was measured weekly. At the end of the treatment, blood insulin, triglycerides, total cholesterol, and protein were measured. Glycogen content and expression of proteins of the insulin signaling pathway were measured in liver. The treatment with 600 mg/Kg reduced the fasting blood glucose in diabetic mice of the 7th day as water and food intake and increased hepatic glycogen. Total cholesterol and triglycerides were reduced in diabetic treated mice. The treatment increased the expression of IRS-1, PI3-K, and AKT in the livers of diabetic treated mice. The results indicate that the extract of the leaves of Myrcia bella has hypoglycemic properties and possibly acts to regulate glucose uptake by the liver.

Highlights

  • Diabetes is a metabolic disorder characterized by chronic hyperglycemia as a result of defects in insulin action, insulin secretion, or both

  • The flow injection analysis (FIA)-ESIMS/MSn analysis of the 70% EtOH extract highlighted the presence of precursor ions related to phenolic acids, flavonoid aglycones, flavonoid-O-glycosides, and acylated flavonoidO-glycosides (Figure 1)

  • We investigated the hypoglycemic activity of the extract of leaves of Myrcia bella administered to streptozotocin-induced diabetic mice

Read more

Summary

Introduction

Diabetes is a metabolic disorder characterized by chronic hyperglycemia as a result of defects in insulin action, insulin secretion, or both. This disorder results in abnormality in protein, lipid, and carbohydrate metabolism, leading to long-term complications, such as neuropathy, nephropathy, retinopathy, atherosclerosis, and peripheral vascular disease [1]. In 1985, it was estimated that there were 30 million people with diabetes worldwide, and this number dramatically increased in the ensuing 10 years, reaching 135 million people. Estimates indicate that this number, by 2030, should grow to 366 million people with this syndrome, of which 90% will develop type 2 diabetes (DM2). It is estimated that there are about 12 million diabetic patients in Brazil [2]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call